anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain the titled fraction usable as an antibody in immunochemical assay, by treating an immunoglobulin prepared from rodents at a specific pH. CONSTITUTION:An immunoglobulin obtained from rodents is treated with pepsine at 2-4pH to give an immunoglobulin F(ab')2. The amount of the immunoglobulin in carrying out the above-mentioned treatment is 0.1-3wt./ vol.%, preferably 0.3-1wt./vol.%. If the pH in the treatment with the pepsine is adjusted to a more acidic side, the F(ab')2 can be efficiently obtained. Examples of the pepsine include pepsine prepared by freeze-drying crystalline pepsine obtained from porcine gastric mucus, etc. The concentration of the pepsine is 1/40-2 times based on the amount of the immunoglobulin. The above- mentioned treatment is preferably carried out in a buffer solution, e.g. 0.1M acetic acid buffer solution, etc.
There are few reports of poisoning caused by high-dose intravenous injection of mercury. Its clinical manifestations are diverse and the risk of mortality is high. Currently, the pathogenesis is not clear and the treatment experience is insufficient, leading to difficulties in clinical diagnosis and treatment. In this article, the data of a case of mercury poisoning caused by intravenous self-administration was analyzed and summarized. The patient developed multiple organ dysfunction syndrome after intravenous injection of high-dose mercury. After comprehensive treatment, such as mercury removal, organ support, and infection prevention, the condition was improved. This case suggests that intravenous injection of mercury can cause damage to the functions of multiple organs, such as the heart, lungs, and kidneys. Early treatment and intervention can bring benefits.
A homogeneous allergen-laden atmosphere of chosen concentration and chosen MMAD is created by means of an ultrasound nebulizer (9), an aqueous composition of allergens (8) and a stream of pure air (13). To this end, the concentration and flow rate of the allergen composition and the frequency of the nebulizer are calculated, allowing these parameters to be obtained. The nebulizate obtained is mixed with the stream of pure air outside the exposure room (2). The resultant stream is introduced into the exposure room by diffusion outlets (21) positioned high up, and is sucked out by one or more discharge outlets (22) positioned close to floor level. Particular measurements are continuously monitored to ensure that safety thresholds are not exceeded. Prior to that, the efficiency of the nebulizer is measured, the concentration and MMAD of the allergens obtained in the exposure room are checked and the distribution of the stream is homogenized by adjusting the opening of each discharge outlet.
PURPOSE:To obtain a solid powdery cosmetic having excellent practical characteristics such as spreadability on skin, adherability to skin, make-up durability, refreshing feeling and excellent impact resistance, containing an oily component of specific composition and a powdery component. CONSTITUTION:3-15wt.% oily component and 85-97wt.% powdery component are properly blended with a surfactant, a colorant, an antiseptic, an antioxidant, an ultraviolet light absorber and a perfume and prepared to give the objective substance. 1-6wt.% ester compound between (e.g. propylene glycol dicaprate) of 8-18C straight-chain saturated fatty acid mixture and glycerol, and 1-6wt.% ester compound of 8-10C straight-chain saturated fatty acid and a specific polyhydric alcohol (e.g. propylene glycol) are contained as the oily component. The amount of both ester components blended is >=30wt.% of the whole oily component.
The invention relates to a natural antioxidant peptide Tiannanin-beta1 and preparation method and application thereof. The natural antioxidant peptide Tiannanin-beta1 is a gene-encoding product and has the following sequence from the N-terminal to C-terminal: VVKFPYRCKAAF. The natural antioxidant peptide is prepared from the skin of Odorrana frogs which can only be found in China and exits in the frog skin to play a major role of protecting the exposed skin from ultraviolet injury. The antioxidant peptide Tiannanin-beta1 is applied to cosmetic production, is original and pure natural, and conforms to the consumption requirements for modern people. The activity of the antioxidant peptide is 1000 times higher than that of the conventional antioxidant BHT. Besides the antioxidant activity, the peptide Tiannanin-beta1 also has antimicrobial activity, immunoregulatory activity and melanin formation inhibitory activity.
Coccydynia is pain in the coccygeal region, and usually treated conservatively. Extracorporeal shock wave therapy (ESWT) was incorporated as non-invasive treatment of many musculoskeletal conditions. However, the effects of ESWT on coccydynia are less discussed. The purpose of this study is to evaluate the effects of ESWT on the outcomes of coccydynia. Patients were allocated to ESWT (n=20) or physical modality (SIT) group (n=21) randomly, and received total treatment duration of 4 weeks. The visual analog scale (VAS), Oswestry disability index (ODI), and self-reported satisfaction score were used to assess treatment effects. The VAS and ODI scores were significantly decreased after treatment in both groups, and the decrease in the VAS score was significantly greater in the ESWT group. The mean proportional changes in the ODI scores were greater in the ESWT group than in the SIT group, but the between-group difference was not statistically significant. The patients in the ESWT group had significantly higher subjective satisfaction scores than SIT group. The investigators concluded that ESWT is more effective and satisfactory in improving discomfort and disability caused by coccydynia than the use of physical modalities. Thus, ESWT is recommended as an optimal treatment option for patients with coccydynia.
We describe how increased root cortical parenchyma wall width (CPW) can improve tolerance to drought stress in maize by reducing the metabolic costs of soil exploration. Significant variation (1.0-5.0 µm) for CPW was observed in maize germplasm. The functional-structural model RootSlice predicts that increasing CPW from 2 µm to 4 µm is associated with a ~15% reduction in root cortical cytoplasmic volume, respiration rate, and nitrogen content. Analysis of genotypes with contrasting CPW grown with and without water stress in the field confirms that increased CPW is correlated with an ~32-42% decrease in root respiration. Under water stress in the field, increased CPW is correlated with 125% increased stomatal conductance, 325% increased leaf CO2 assimilation rate, 73-78% increased shoot biomass, and 92-108% increased yield. CPW was correlated with leaf mesophyll midrib parenchyma wall width, indicating pleiotropy. Genome-wide association study analysis identified candidate genes underlying CPW. OpenSimRoot modeling predicts that a reduction in root respiration due to increased CPW would also benefit maize growth under suboptimal nitrogen, which requires empirical testing. We propose CPW as a new phene that has utility under edaphic stress meriting further investigation.
FIELD: veterinary. SUBSTANCE: individual foot bath with preliminary added drug is put on the hoofs to animal with damaged limbs. Foot bath is fixed. Ointment of the following composition is used as a drug, wt.-%: veterinary copper sulfate 7.5-15; birch tar 9.0-13; ichthyol 3-5, and vaselin - the rest. Contact duration is 3-10 days. Ointment has additionally vagotyl and/or cubatol (4-7%) used in the cases of heavy disease form. Ointment can be prepared by preliminary mechanical mixing of components indicated at 36-40 C. EFFECT: enhanced efficacy of treatment. 2 cl
B-CBT is based on the same treatment principles as face-to-face Cognitive Behavioral Therapy (CBT). These include (a) psycho-education about depression, (b) cognitive restructuring (i.e., identifying and challenging maladaptive thoughts and beliefs, fostering problem solving capacities), (c) mindfulness and acceptance based approaches, and (d) relapse prevention. B-CBT in this trial consists of 8 online modules that are alternated with up to 8 fortnightly face-to-face sessions.
The same surgical procedure will be operated in the test and control groups by the same surgeon. Full-thickness flaps were raised and dental implant osteotomy preparation will be completed according to the manufacturers' instructions. Laser treatment will be completed using Gallium-Aluminum-Arsenide diode laser. The photobiomodulation application will v-be completed by laser energy immediately and three times a week for just 15 days after surgery. The control group will consist of laser application without energy delivery to the tissue. Immediately after implant placement, the third generation stability resonance frequency (RF) analyzer will be applied for direct measurement of implant stability and the value will be recorded. The microbiological plaque samples will be collected at specific times, according to the following schedule; at the first 24-hour and 90 days after implant surgery. All bacterial DNA specimen will be analyzed with qPCR technique to evaluate Aggregatibacter actinomycetemcomitans (Aa), Porphyromonas gingivalis (Pg), Prevotella intermedia (Pi) , Tannerella forsythia (Tf ) and total amount of bacteria.
In this pragmatic, cluster randomized crossover trial 42 Skilled Nursing Facilities (SNF) will each receive 6 months of each care model in random sequence. All patients with OP fracture admitted to the SNF within the intervention time period will receive the full designated care model, even if their stay in the SNF extends into the next intervention period.
A method and composition for non-invasive treatment of skin aging conditions utilizes a topically applied composition that includes a sustainable non GMO water based extract of peptide Sacha Inchi (hydrolyzed Plukenetia Volubilis Seed Extract). The composition utilizes Sacha Inchi to clinically and non-invasively reduce after only 28 days skin sagginess and facial volume contour. Reshaping and resculpting facial skin and reducing dermal non-echogenic surfaces are also accomplished. Increased echogenic surfaces, increased dermal connective tissue and dermal density by restructuring, re-densifying and revitalizing dermis for healthier skin is furthered. The composition was clinically proven to reduce after only 21 days of treatment fine lines, deep wrinkles and facial skin roughness, for a smoother, healthier, younger and less wrinkled skin. The composition was also clinically proven to reduce sebum production, minimize pore size, mattifying skin appearance by sebum regulation and smoothing the appearance of skin after only 21 days of treatment.
BACKGROUND: Much remains unknown about how complex community-based programmes can successfully achieve long-term impact. More insight is needed to understand the key mechanisms through which these programmes work. Therefore, we conducted an in-depth study in five communities that implemented the Healthy Youth, Healthy Future (JOGG) approach, a Dutch community-based obesity prevention programme. We aimed to identify perceived outcomes and long-term impacts among local stakeholders and explore potential causal pathways and working mechanisms.
METHODS: We used ripple effects mapping (REM), a qualitative participatory method to map outcomes and identify causal pathways, in five communities. We involved 26 stakeholders, professionals and policy-makers affiliated with the local JOGG approach, spread over eight REM sessions and conducted individual interviews with 24 additional stakeholders. To uncover working mechanisms, we compared outcomes and causal pathways across communities.
RESULTS: Over 5-9 years of implementation, participants perceived that JOGG had improved ownership of local stakeholders, health policies, intersectoral collaboration and social norms towards promoting healthy lifestyles. Causal pathways comprised small initial outcomes that created the preconditions to enable the achievement of long-term impact. Although exact JOGG actions varied widely between communities, we identified five common working mechanisms through which the JOGG approach contributed to causal pathways: (1) creating a positive connotation with JOGG, (2) mobilizing stakeholders to participate in the JOGG approach, (3) facilitating projects to promote knowledge and awareness among stakeholders while creating successful experiences with promoting healthy lifestyles, (4) connecting stakeholders, thereby stimulating intersectoral collaboration and (5) sharing stakeholder successes that promote healthy lifestyles, which gradually created a social norm of participation.
CONCLUSIONS: The JOGG approach seems to work through activating initial stakeholder participation and bolstering the process towards ownership, policy change, and intersectoral collaboration to promote healthy lifestyles. Key working mechanisms can inform further development of JOGG as well as other complex community-based prevention programmes.
The sample will be evaluated once a day in the morning until they complete at least 11 intervention sessions of hydrotherapy in five moments: immediately before therapy, immediately after, 15, 30 and 60 minutes after the intervention. While they are in need of intensive care and hospitalized in the NICU, infants allocated to GH, hydrotherapy will be performed once a day, associated with two sessions of conventional physiotherapy. After discharge to the intermediate care unit (ICU), patients will receive care only once a day, both conventional physiotherapy and hydrotherapy. Evaluations and interventions will be carried out five days a week (Monday to Friday), according to the logistics of the unit.
The placebo control will be maltodextrin powder in identical sachets. Participants will mix the powder into 250 mL water and consume two such beverages daily, ≥1 hour apart. (For the first week, all participants will consume one beverage daily, and subsequently increase to one beverage twice daily.) Participants will be requested to substitute these for 500 mL of their usual daily water intake but to make no other dietary changes.
BACKGROUND: Midurethral slings are the gold standard for treating stress urinary incontinence, but their complications may raise concerns. Complications may differ by the approach used to place them.
OBJECTIVE: This study aimed to compare serious complications and reoperations for recurrence after midurethral sling procedures when using the retropubic vs the transobturator route for female stress urinary incontinence.
STUDY DESIGN: This analysis was of patients included in the French, multicenter VIGI-MESH register since February 2017 who received a midurethral sling for female stress urinary incontinence either by the retropubic or the transobturator route and excluded patients with single-incision slings. Follow-up continued until October 2021. Serious complications (Clavien-Dindo classification ≥ grade III) attributable to the midurethral sling and reoperations for recurrence were compared using Cox proportional hazard models including any associated surgery (hysterectomy or prolapse) and a frailty term to consider the center effect. Baseline differences were balanced by propensity score weighting. Analyses using the propensity score and Cox models were adjusted for baseline differences, center effect, and associated surgery.
RESULTS: A total of 1830 participants received a retropubic sling and 852 received a transobturator sling in 27 French centers that were placed by 167 surgeons. The cumulative 2-year estimate of serious complications was 5.8% (95% confidence interval, 4.8-7.0) in the retropubic group and 2.9% (95% confidence interval, 1.9-4.3) in the transobturator group, that is, after adjustment, half of the retropubic group was affected (adjusted hazard ratio, 0.41; 95% confidence interval, 0.3-0.6). The cumulative 2-year estimate of reoperation for recurrence of stress urinary incontinence was 2.7% (95% confidence interval, 2.0-3.6) in the retropubic group and 2.8% (95% confidence interval, 1.7-4.2) in the transobturator group with risk for revision for recurrence being higher in the transobturator group after adjustment (adjusted hazard ratio, 1.9; 95% confidence interval, 1.2-2.9); this surplus risk disappeared after exclusion of the patients with a previous surgery for stress urinary incontinence.
CONCLUSION: The transobturator route for midurethral sling placement is associated with a lower risk for serious complications but a higher risk for surgical reoperation for recurrence than the retropubic route. Despite the large number of surgeons involved, these risks were low. The data are therefore reassuring.
The invention discloses a mycoplasma ovipneumoniae strain, a vaccine prepared from the strain and application of the vaccine. The mycoplasma ovipneumoniae strain is obtained by separating a diseased sheep and is named as WM01 strain, is preserved in the China general microbiological culture Collection center, and has the strain preservation numbers of: CGMCC No. 19979. The mycoplasma ovipneumoniae WM01F6 strain obtained by separation is prepared into an inactivated vaccine, or is prepared into a bivalent inactivated vaccine together with the parainfluenza virus type 3, and safety tests show that all test sheep of single vaccine and bivalent vaccine have no local and systemic adverse reactions after being inoculated with the vaccine. The efficacy test result shows that the vaccine can generate better protection effect on virulent attack after immunizing experimental animals, and the protection rate is at least 80%. Therefore, the invention provides an effective technical means for preventing the respiratory diseases of the sheep.
The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
Regardless of the quantity of acetaminophen reported to have been ingested, administer acetylcysteine immediately if 24 hours or less have elapsed from the reported time of ingestion of an overdose of acetaminophen. Do not await results of assays for acetaminophen level before initiating treatment with acetylcysteine. The following procedures are recommended:

  1. The stomach should be emptied promptly by lavage or by inducing emesis with syrup of ipecac. Syrup of ipecac should be given in a dose of 15 mL for children up to age 12 and 30 mL for adolescents and adults followed immediately by drinking copious amounts of water. The dose should be repeated if emesis does not occur in 20 minutes. 
  2. In the case of a mixed drug overdose activated charcoal may be indicated. However, if activated charcoal has been administered, lavage before administering acetylcysteine treatment. Activated charcoal adsorbs acetylcysteine in vitro and may do so in patients and thereby may reduce its effectiveness. 
  3. Draw blood for predetoxification acetaminophen plasma assay and baseline SGOT, SGPT, bilirubin, prothrombin time, creatinine, BUN, blood sugar and electrolytes. 
  4. Administer the loading dose of acetylcysteine, 140 mg per kg of body weight. (Prepare acetylcysteine for oral administration as described in the Dosage Guide and Preparation table). 
  5. Determine subsequent action based on predetoxification plasma acetaminophen information. Choose ONE of the following four courses of therapy. 
    1. Predetoxification plasma acetaminophen level is clearly in the toxic range (See Acetaminophen Assays - Interpretation and Methodology below):  
Administer a first maintenance dose (70 mg/kg acetylcysteine) 4 hours after the loading dose. The maintenance dose is then repeated at 4-hour intervals for a total of 17 doses. Monitor hepatic and renal function and electrolytes throughout the detoxification process.
    2. Predetoxification acetaminophen level could not be obtained  
Proceed as in A.
    3. Predetoxification acetaminophen level is clearly in the non-toxic range (beneath the dashed line on the nomogram) and you know that acetaminophen overdose occurred at least 4 hours before the predetoxification acetaminophen plasma assays  
Discontinue administration of acetylcysteine.
    4. Predetoxification acetaminophen level was in the non-toxic range, but time of ingestion was unknown or less than 4 hours  
Because the level of acetaminophen at the time of predetoxification assay may not be a peak value (peak may not be achieved before 4 hours post-ingestion), obtain a second plasma level in order to decide whether or not the full 17-dose detoxification treatment is necessary.
  6. If the patient vomits an oral dose within 1 hour of administration, repeat that dose. 
  7. In the occasional instances where the patient is persistently unable to retain the orally administered acetylcysteine, the antidote may be administered by duodenal intubation. 
  8. Repeat SGOT, SGPT, bilirubin, prothrombin time, creatinine, BUN, blood sugar and electrolytes daily if the acetaminophen plasma level is in the potentially toxic range as discussed below.
We report 2 cases of portal vein stent placement for malignant portal stenosis due to recurrence of pancreatic cancer with symptoms of portal hypertension. Case 1: The patient was a 68-year-old female. Five years ago, a mass was found around the aorta on a computerized tomography(CT)scan taken after a residual pancreatectomy for pancreatic cancer. It was diagnosed as lymph node recurrence and S-1 therapy was started. As further tumor enlargement led to portal vein compression, venostasis around the ascending jejunum, anemia, and black stools, a portal vein stent was placed. The portal vein blood flow was improved, the collateral vessels disappeared, and the patient no longer experienced anemia or black stool. Case 2: A 75-year-old female patient underwent a subtotal gastric-sparing pancreaticoduodenectomy and combined resection of the portal vein for pancreas head cancer. On a postoperative CT scan taken 6 months later, a mass compressing the portal vein appeared, which was diagnosed as a local recurrence. As thrombocytopenia was observed, a portal vein stent was placed before starting chemotherapy. The portal vein blood flow and the platelet count improved. Portal vein stenting is an effective procedure for malignant portal stenosis, improving portal blood flow and clinical symptoms.
<P>PROBLEM TO BE SOLVED: To provide a highly safe new apoptosis-inducing agent originated from coffee beans, to provide a food, a drink and a medicine each containing the same, and to provide a method for producing the apoptosis-inducing agent.  <P>SOLUTION: This apoptosis-inducing agent is characterized by containing as an active ingredient an extract obtained by extracting raw coffee beans as the seed portions of coffee fruits or roasted coffee beans with a water-containing ethanol. The apoptosis-inducing agent is originated from the natural plant, has high safety, and exhibits the sure apoptosis-inducing action. The drink and food each contains 0.05 % of the apoptosis-inducing agent containing a coffee bean extract as an active ingredient. The medicine contains the apoptosis-inducing agent containing the coffee bean extract as the active ingredient in an amount of 1 mg/once for each adult. The method for producing the apoptosis-inducing agent comprises refluxing and extracting ground coffee beans with 50°C, 50 % water-containing ethanol for 2 hr, filtering, and then drying.  <P>COPYRIGHT: (C)2005,JPO&NCIPI